Assenagon Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Assenagon Asset Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-289,387	Closed	-$1.16M	–	1287
2020 Q1	$1.16M	Buy	+289,387	New	+$2.46M	0.01%	491
2019 Q2	–	Sell	-55,730	Closed	-$511K	–	1231
2019 Q1	$511K	Sell	55,730 -114,228	-67%	-$1.16M	﹤0.01%	804
2018 Q4	$1.86M	Buy	+169,958	New	+$2.14M	0.02%	474

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management's KIN Position: Q2 2020 in Review

Assenagon Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 289,387 shares — an estimated $1.16M sold.

Assenagon Asset Management first reported a position in KIN in Q4 2018 and held it in 3 quarters. The position peaked at $1.86M in Q4 2018. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

Assenagon Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
Assenagon Asset Management sold 289,387 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $1.16M.
Assenagon Asset Management first reported a position in Kindred Biosciences, Inc. in Q4 2018 and held it in 3 quarters.
Assenagon Asset Management's Kindred Biosciences, Inc. position peaked at $1.86M in Q4 2018.
83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Assenagon Asset Management's 13F filing for Q2 2020, filed 21 Jul 2020.